General Announcement::Glenmark Pharmaceuticals & Hikma enter into an Exclusive Licensing Agreement

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
27-Feb-2020 15:40:07
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals & Hikma enter into an Exclusive Licensing Agreement
Announcement Reference
SG200227OTHR2B24
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
27/02/2020 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals and Hikma enter into an Exclusive Licensing Agreement for commercializing Ryaltris Seasonal Allergic Rhinitis Nasal Spray in the US

Attachments

SGX_PR_27.02.2020.pdf
Total size =770K